In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Stereotactic radiosurgery in the treatment of parasellar meningiomas: long-term volumetric evaluation.

    Final Number:
    4049

    Authors:
    Or Cohen-Inbar MD PhD; tata ba athreya; Shayan Moosa BA; Cheng-Chi Lee MD; Jason P. Sheehan MD PhD FACS

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting - Late Breaking Science

    Introduction: Stereotactic radiosurgery (SRS) has played a central role in the treatment of parasellar meningiomas. Evaluation of tumor control rates at this location using simplified single-dimension measurements may prove misleading. The authors report the influence of SRS treatment parameters and volumetric changes of benign WHO Grade I parasellar meningiomas after SRS on long-term outcome.

    Methods: A total of 189 patients (22.2% males, n = 42) form the cohort. SRS was performed as a primary upfront treatment for 44.4% (n = 84). Median tumor volume 5.6 cm3 (0.2-54.8 cm3). Median margin dose 14 Gy (5-35 Gy). The volumes of the parasellar meningioma were computed by segmenting the meningioma on a slice-by-slice basis with numerical integration using the trapezoidal rule.

    Results: Median follow-up was 71 months (6-298). Tumor volume control achieved in 91.5% (n = 173). Post-SRS, new or worsening CN deficits were observed in 54 instances(19 trigeminal nerve and 18 optic nerve). Of these, 90.7% (n = 49) were due to tumor progression. Overall, this translates to a 2.64% incidence of SRS-related complications. For patients treated with a margin dose =16 Gy, the 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial progression-free survival rates are 100%, 100%, 95.7%, 95.7%, 95.7%, 95.7%, and 95.7%, respectively. Patients treated with a margin dose < 16 Gy, had 2-, 4-, 6-, 8-, 10-, 12-, and 15-year actuarial progression-free survival rates of 99.4%, 97.7%, 95.1%, 88.1%, 82.1%, 79.4%, and 79.4%, respectively. This difference was significant (p = 0.043). Reviewing the volumetric patient-specific measurements, the early follow-up volumetric measurements (at the 3-year follow-up) reliably predicted long-term volume changes and tumor volume control (p = 0.029).

    Conclusions: SRS is a durable and minimally invasive treatment modality for benign parasellar meningiomas. Volumetric regression or stability during short-term follow-up of 3 years after SRS was shown to be predictive of long-term tumor control.

    Patient Care: SRS is a leading approach in treating complex parasellar lesions

    Learning Objectives: report the influence of SRS on long-term outcome.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy